FDA rejects expanded use of Pacira's Exparel
This article was originally published in Scrip
Executive Summary
Shares of Pacira Pharmaceuticals plummeted about 20% on 2 March after the FDA rejected the expanded use of the firm's long-acting non-opioid postsurgical analgesic Exparel (bupivacaine extended-release liposome injection) as a therapy to block nerve pain.